A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02294877|
Recruitment Status : Recruiting
First Posted : November 19, 2014
Last Update Posted : July 15, 2020
|Condition or disease||Intervention/treatment|
|Mucopolysaccharidosis IV Type A Morquio A Syndrome MPS IVA||Drug: Vimizim® (elosulfase alfa)|
MARS is a multicenter, multinational, observational disease registry for patients diagnosed with Mucopolysaccharidosis Type IVA (MPS IVA). The Registry will collect medical history, and clinical and safety assessments every six months, for up to 10 years. The Registry will enroll and collect data on patients over a period of at least 8 years from the time of the first marketing approval globally and data on individual patients will continue to be collected for at least 2 years from the time the last patient was enrolled or until the Registry is completed.
These assessments are designed to further characterize the spectrum of clinical signs and symptoms of the disease, and to further characterize the safety profile of Vimizim in a broader population. It is not required that patients receive Vimizim to be eligible to participate in this Registry.
In addition, this Registry will collect additional data on patients who have completed the MOR-005 and MOR-007 clinical trials. The MOR-005 and MOR-007 clinical trial patients will be enrolled into the appropriate Registry Substudy for a minimum of 5 years from the time of the patient's enrollment in the MOR-005 clinical study or MOR-007 clinical study. After the 5 year period, these patients should remain in MARS until the Registry is complete.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||583 participants|
|Target Follow-Up Duration:||10 Years|
|Official Title:||A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||September 2024|
|Estimated Study Completion Date :||September 2024|
- Drug: Vimizim® (elosulfase alfa)
Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)Other Name: BMN 110
- Safety of Vimizim treated patients as measured by the incidences of Adverse Events, Serious Adverse Events, and immunology tests [ Time Frame: 10 Years ]
Additional safety measures are medications, occurrence of Bone Marrow Transplant/Hematopoietic Stem Cell Transplant, clinical laboratory tests, vital signs, Electrocardiograms, Echocardiograms, immunogenicity results, physical examinations, imaging studies, and cervical spine imaging.
All assessments in this observational study will be carried out per the participating institution's standard of care.
The MARS Annual report will descriptively summarize the safety and outcome measurements for the duration of this voluntary, observational study.
- Efficacy of Vimizim as measured by the 6MWT, 3MSCT, RFTs, FEV1, FIVC, FVC, and MVV [ Time Frame: 10 years ]Efficacy of Vimizim as measured by the changes in the 6 minute walk test (6MWT), 3 minute stir climb test (3MSCT), respiratory function tests (RFTs) including forced expiratory volume for 1 second (FEV1), forced inspiratory vital capacity (FIVC), forced vital capacity (FVC), and maximum voluntary ventilation (MVV) and by urinary Keratan Sulfate.
- The MARS Pregnancy Substudy will collect safety data measured by Adverse Events, Serious Adverse Events, immunology tests, and the infant outcomes as measured by a live birth [ Time Frame: 10 years ]The MARS Pregnancy Substudy will collect safety data on the outcomes of pregnancy in women who receive Vimizim as measured by Adverse Events, Serious Adverse Events, immunology tests, and the infant outcomes as measured by a live birth.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02294877
|Contact: Trial Specialistfirstname.lastname@example.org|
|Study Director:||Medical Director, MD||BioMarin Pharmaceutical|